GARHENG KONG, M.D., PH.D.

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

LABCORP HOLDINGS INC.

Filing Date Source Excerpt
2024-04-04 Garheng Kong has served as a director of the Company since December 2013 and Lead Independent Director since June 2023. Dr. Kong also serves as the Chair of the Nominating and Corporate Governance Committee for the Company.
2025-04-04 Garheng Kong has served as a director of the Company since December 2013 and Lead Independent Director since June 2023. Dr. Kong also serves as the Chair of the Nominating and Corporate Governance Committee for the Company. ... Committees: Lead Independent Director, Compensation and Human Capital Committee, Nominating and Corporate Governance Committee (Chair). Summary of 2024 Director Compensation: Garheng Kong total compensation in 2024 was $395,000.

Ocugen, Inc.

Filing Date Source Excerpt
2015-04-28 Dr. Kong holds a B.S. from Stanford University. He holds an M.D., Ph.D. and an M.B.A. from Duke University.
2016-04-28 Dr. Kong holds a B.S. from Stanford University. He holds an M.D., Ph.D. and an M.B.A. from Duke University. We believe that Dr. Kong’s qualifications to serve as a director of our company include his knowledge and experience in the venture capital industry, his medical training and his significant prior board experience with both public and privately held companies.
2016-11-02 Garheng Kong, M.D., Ph.D. includes 20,000 shares of Common Stock issuable upon exercise of options exercisable within 60 days of October 18, 2016.
2017-04-27 Dr. Kong holds a B.S. from Stanford University. He holds an M.D., Ph.D. and an M.B.A. from Duke University. We believe that Dr. Kong’s qualifications to serve as a director of the Company include his knowledge and experience in the venture capital industry, his medical training and his significant prior board experience.
2018-04-26 Dr. Kong holds a B.S. from Stanford University. He holds an M.D., Ph.D. and an M.B.A. from Duke University. We believe that Dr. Kong’s qualifications to serve as a director of the Company include his knowledge and experience in the venture capital industry, his medical training and his significant prior board experience with both public and privately held companies.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22